Newsletter | November 18, 2026

11.18.26 -- Will Your Next-Gen Conjugate Survive Scale-Up?

Advances In Chemistry Enable Next-Generation Targeted Bioconjugates

Advanced chemical strategies improve targeted bioconjugates, but scaling production requires aligning early design choices with robust manufacturing workflows. Read the full resource to master these critical development considerations.

 

Why Process Efficiency & Advanced Conjugation Expertise Outweigh Capacity

Navigating complex therapeutic scale-up successfully requires prioritizing technical mastery and workflow efficiency over raw facility capacity. Optimizing bioprocessing methods early helps developers streamline production, minimize variability, and overcome bottlenecks.

 

White Paper: Designing, Selecting, And Developing Bioconjugates For Clinical Success

Ready to kick-start your bioconjugate R&D program? Learn from real-world case studies that demonstrate how to accelerate the development of complex bioconjugates and unlock new possibilities for targeted therapies with greater precision.

 

Case Study: AOC GMP Manufacture For A FIH Study

Advancing complex AOCs into clinical trials relies on coordinated workflows, analytical rigor, and flexible manufacturing capabilities. Mastering these parameters ensures high-quality material delivery and accelerates timelines.

 

VIDEO FEATURE

Abzena Capacity Update: Dual-Payload ADCs

In this on-demand presentation, discover how our integrated expertise can help you develop and manufacture dual payload ADCs with optimized efficacy, precision conjugation, and scalable solutions.

 

SOLUTIONS

Leveraging Complex Chemistry To Improve The Design & Delivery Of Bioconjugates

Our extensive experience allows us to deliver scalable, high-quality solutions tailored to the most challenging molecular constructs, ensuring both efficiency and safety in the production of these advanced therapeutic modalities.